Boehringer Ingelheim makes million-euro investment in fight against antibiotic resistance

The pharmaceutical firm is investing EUR 30m in a new biotech company focused on precision medicine to treat infections.

Photo: Boehringer Ingelheim / PR

German pharmaceutical firm Boehringer Ingelheim is investing EUR 30m to combat drug-resistant bacteria. Forming an alliance with Evotec and Biomérieux, the firms have established Aurobac Therapeutics, a biotech firm with a precision medicine approach to infection treatment, as reported by Fierce Biotech.

It’s been estimated that antibiotic-resistant bacteria cost the lives of 1.27 million people each year, and studies have projected that by 2050, AMR will be the cause of 10 million deaths annually, costing the global economy USD 100bn a year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs